A Prospective, Multicenter, Randomized Controlled Study of Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
Latest Information Update: 04 Aug 2023
At a glance
- Drugs Docetaxel (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PIONEER
- 22 Jan 2022 Patient enrollment is expected to be completed in June 2022, as per trial design presented at the 2022 Gastrointestinal Cancers Symposium
- 22 Jan 2022 Trial design presented at the 2022 Gastrointestinal Cancers Symposium
- 22 Jan 2022 Status changed from not yet recruiting to recruiting ,as per trial design presented at the 2022 Gastrointestinal Cancers Symposium